Investor Presentation

AI summary - Q2 FY27 revenue ₹4,369 Mn +42.7% y-y; EBITDA ₹1,760 Mn +84.6% y-y; PAT ₹1,231 Mn +71.4% y-y - FY27 revenue growth guidance raised from 25% to ~30% - EBITDA margin guidance increased to 38-40% range for FY27 - South Korea manufacturing facility inaugurated ahead of schedule for semiconductor chemicals - Pharma Intermediates segment showed strong growth; Specialty Chemicals declined due to strategic phasing out - H1 FY27 revenue ₹7,666 Mn +49.3% y-y; EBITDA margin 37.7%; PAT margin 25.8% - Superior margins driven by higher gross margins and operating leverage - PAT margin strength offset by higher depreciation and lower other income